HUTCHMED (China) Limited (HCM) Financials

NASDAQ:HCM

Market Cap

2.79B

Total Revenue

426.41M

Gross Profit

115.31M

Operating Income

-409.77M

Net Income

-410.14M

Metric	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022
revenue	45,970,000	91,813,000	178,203,000	216,080,000	241,203,000	214,109,000	204,890,000	227,976,000	356,128,000	426,409,000
costOfRevenue	22,208,000	72,049,000	110,777,000	156,328,000	175,820,000	143,944,000	160,152,000	188,519,000	258,234,000	311,103,000
grossProfit	23,762,000	19,764,000	67,426,000	59,752,000	65,383,000	70,165,000	44,738,000	39,457,000	97,894,000	115,306,000
researchAndDevelopmentExpenses	--	--	47,368,000	66,871,000	50,675,000	78,821,000	91,944,000	111,234,000	207,447,000	267,587,000
sellingAndMarketingExpenses	3,452,000	4,112,000	10,209,000	17,998,000	19,322,000	17,736,000	13,724,000	11,334,000	37,827,000	43,933,000
generalAndAdministrativeExpenses	21,295,000	22,572,000	19,620,000	21,580,000	23,955,000	30,909,000	39,210,000	50,015,000	89,298,000	92,173,000
sellingGeneralAndAdministrativeExpenses	24,747,000	26,684,000	29,829,000	39,578,000	43,277,000	48,645,000	52,934,000	61,349,000	127,125,000	136,106,000
operatingExpenses	23,144,000	26,866,000	77,197,000	106,588,000	118,800,000	161,008,000	189,757,000	236,125,000	426,211,000	522,999,000
operatingIncome	11,555,000	8,100,000	-9,771,000	-46,697,000	-53,417,000	-92,641,000	-145,019,000	-188,947,000	-336,458,000	-409,770,000
totalOtherIncomeExpensesNet	-1,485,000	-1,516,000	184,000	470,000	-119,000	5,986,000	3,914,000	-787,000	120,718,000	-652,000
ebitda	1,581,000	-5,837,000	-7,121,000	-43,384,000	-49,503,000	-82,056,000	-135,133,000	-182,886,000	-329,268,000	-401,106,000
depreciationAndAmortization	963,000	1,265,000	2,015,000	2,341,000	2,578,000	3,590,000	9,886,000	6,061,000	7,190,000	8,664,000
interestIncome	451,000	559,000	451,000	502,000	1,220,000	5,978,000	4,944,000	3,236,000	2,076,000	9,599,000
interestExpense	1,014,000	1,045,000	1,404,000	1,631,000	1,455,000	1,009,000	1,030,000	787,000	592,000	652,000
incomeBeforeTax	10,070,000	6,584,000	-10,540,000	-47,356,000	-53,536,000	-86,655,000	-141,105,000	-189,734,000	-215,740,000	-410,422,000
incomeTaxExpense	1,050,000	1,343,000	1,605,000	4,331,000	3,080,000	3,964,000	3,274,000	4,829,000	11,918,000	-283,000
netIncome	5,915,000	5,374,000	7,993,000	11,698,000	-26,737,000	-74,805,000	-144,379,000	-194,563,000	-227,658,000	-410,139,000
eps	0.057	0.051	-0.32	0.1	-0.22	-0.56	-1.08	-1.39	-1.44	-2.42
epsdiluted	0.056	0.051	-0.32	0.1	-0.22	-0.56	-1.08	-1.39	-1.44	-2.42
weightedAverageShsOut	104,101,976	105,126,774	109,318,630	119,430,346	123,434,342	132,852,764	133,136,629	139,586,287	158,536,905	169,428,708
weightedAverageShsOutDil	105,756,852	105,787,402	109,318,630	119,942,100	123,434,342	132,852,764	133,136,629	139,586,287	158,536,905	169,428,708
costAndExpenses	45,352,000	98,915,000	187,974,000	262,916,000	294,620,000	304,952,000	349,909,000	424,644,000	684,445,000	834,102,000
otherExpenses	65,000	261,000	184,000	609,000	116,000	-781,000	44,879,000	63,542,000	91,639,000	119,306,000

Key Facts

Industry

Drug Manufacturers—Specialty & Generic

Sector

Healthcare

Headquarters

Central, , HK

Website

hutch-med.com

CEO

Dr. Wei-Guo Su B.Sc., Ph.D.

Employees

1990

About the Company

HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, a spleen tyrosine kinase inhibitor for hematological cancers and certain chronic immune diseases; and HMPL-689 for isoform PI3Kd (phosphoinositide 3'-kinase delta). In addition, it develops Tazemetostat, an inhibitor of EZH2 for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-760, an Bruton's tyrosine kinase inhibitor; HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-295 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and Epitinib (HMPL-813) and Theliatinib (HMPL-309) inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. The company was incorporated in 2000 and is headquartered in Central, Hong Kong.